CN110121647A - 用于检测和治疗胰腺导管腺癌的方法 - Google Patents

用于检测和治疗胰腺导管腺癌的方法 Download PDF

Info

Publication number
CN110121647A
CN110121647A CN201780080968.1A CN201780080968A CN110121647A CN 110121647 A CN110121647 A CN 110121647A CN 201780080968 A CN201780080968 A CN 201780080968A CN 110121647 A CN110121647 A CN 110121647A
Authority
CN
China
Prior art keywords
antigen
patient
timp1
lrg1
pancreas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780080968.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·哈纳希
M·卡佩罗
A·田口
Z·冯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas at Austin
Original Assignee
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas at Austin filed Critical University of Texas at Austin
Publication of CN110121647A publication Critical patent/CN110121647A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780080968.1A 2016-12-15 2017-12-15 用于检测和治疗胰腺导管腺癌的方法 Pending CN110121647A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662435020P 2016-12-15 2016-12-15
US201662435024P 2016-12-15 2016-12-15
US62/435,024 2016-12-15
US62/435,020 2016-12-15
PCT/US2017/066851 WO2018112428A1 (en) 2016-12-15 2017-12-15 Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
CN110121647A true CN110121647A (zh) 2019-08-13

Family

ID=62559366

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080968.1A Pending CN110121647A (zh) 2016-12-15 2017-12-15 用于检测和治疗胰腺导管腺癌的方法

Country Status (6)

Country Link
US (3) US20200182876A1 (enExample)
EP (1) EP3555628A4 (enExample)
JP (3) JP2020514689A (enExample)
KR (1) KR102549063B1 (enExample)
CN (1) CN110121647A (enExample)
WO (1) WO2018112428A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110646554A (zh) * 2019-09-12 2020-01-03 北京博远精准医疗科技有限公司 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
RU2745793C1 (ru) * 2020-02-26 2021-04-01 Государственное бюджетное учреждение здравоохранения города Москвы городская клиническая больница имени С.П. Боткина департамента здравоохранения города Москвы (ГБУЗ ГКБ им. С.П. Боткина ДЗМ) Способ расчета средней продолжительности жизни у пациентов с метастатической аденокарциномой поджелудочной железы
CN115125312B (zh) * 2021-03-26 2025-07-18 中国科学院上海营养与健康研究所 用于Basal型胰腺导管腺癌(PDAC)诊断的标志物组合及其应用
CN113917008A (zh) * 2021-09-09 2022-01-11 广州济士源生物技术有限公司 质谱检测尿液中代谢物水平的产品在制备用于早期评估肠道息肉和结直肠癌产品中的应用
CN114487201A (zh) * 2022-02-09 2022-05-13 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 鼻咽癌相关尿液标志物组合的检测试剂的应用
AU2023221839A1 (en) * 2022-02-15 2024-08-22 Kite Pharma, Inc. Predicting adverse events from immunotherapy.
WO2024059549A2 (en) * 2022-09-12 2024-03-21 Board Of Regents, The University Of Texas System Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US20120202188A1 (en) * 2009-10-01 2012-08-09 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012343843B2 (en) * 2011-11-30 2018-03-08 Metanomics Health Gmbh Device and methods to diagnose pancreatic cancer
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
AU2014368412A1 (en) * 2013-12-20 2016-07-07 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US20120202188A1 (en) * 2009-10-01 2012-08-09 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J-Y JANG等: "FP13-03:novel biomarker panel the early detection of pancretic cancer and its clinical validation", 《INTERNATIONAL HEPATO-PANCREATO-BILIARY ASSOCIATION》 *
R.E. BRAND等: "serum biomarker panels for the detection of pancreatic cancer", 《CLINICAL CANCER RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110646554A (zh) * 2019-09-12 2020-01-03 北京博远精准医疗科技有限公司 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用

Also Published As

Publication number Publication date
KR102549063B1 (ko) 2023-06-28
US20230324394A1 (en) 2023-10-12
JP2025118850A (ja) 2025-08-13
US20250298025A1 (en) 2025-09-25
EP3555628A1 (en) 2019-10-23
KR20190101395A (ko) 2019-08-30
JP2023055806A (ja) 2023-04-18
JP2020514689A (ja) 2020-05-21
US20200182876A1 (en) 2020-06-11
EP3555628A4 (en) 2020-08-05
WO2018112428A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US20250298025A1 (en) Methods for the detection and treatment of pancreatic ductal adenocarcinoma
US10487363B2 (en) Compositions and methods for detecting neoplasia
JP2020101552A (ja) 乳癌検出用唾液バイオマーカー、及び、これを用いた乳癌患者を健常者から識別する方法
Tan et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer
Pedersen et al. Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics
CN107076748A (zh) 评估乳腺癌的生物标志物
Chen et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel‐assisted digestion and iTRAQ labeling mass spectrometry
CN110291397A (zh) 肺癌的检测和治疗方法
EP3071972B1 (en) Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence
Chinello et al. The proteomic landscape of renal tumors
CN120188046A (zh) 鉴定胰腺癌的方法
Baichan et al. Proteomic analysis identifies dysregulated proteins and associated molecular pathways in a cohort of gallbladder cancer patients of African ancestry
Bhat et al. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan
Yu et al. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor
Chen et al. UHPLC-HRMS-based serum untargeted lipidomics: phosphatidylcholines and sphingomyelins are the main disturbed lipid markers to distinguish colorectal advanced adenoma from cancer
White et al. Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma
Kovacevic et al. Urine proteomic analysis in cystinuric children with renal stones
Vareed et al. Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma
US20220178924A1 (en) Systems and methods for identifying subtype, prognosis, and monitoring of breast cancer
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
EP3559674B1 (en) A method to determine braf mutations and wild type braf protein by mass spectrometry
Zou et al. Small molecules as potential biomarkers of early gastric cancer: A mass spectrometry imaging approach
Uemura et al. Current status of proteomics of esophageal carcinoma
Rakhshan et al. Applications of mass spectroscopy in understanding cancer proteomics
Stella Identification of molecular alterations associated with the progression of clear cell Renal Cell Carcinoma by mass spectrometric approaches

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination